ICInés Castro-Dionicio

Inés Castro-Dionicio

*This is an algorithmically generated author record based on publicly available information.

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Inés Castro-Dionicio has a total of 139 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Objective Evaluation of Untargeted Metabolomic Methods Based on Data-Dependent Acquisition and Public Spectral Databases

    by Romina Pacheco-Tapia, Inés Castro-Dionicio, Mickaël Chevalier, Coralie Berthier, Jean-Michel Lecerf, AmélIe Bonnefond, Philippe Froguel, Francesc Puig-Castellví, Marc-Emmanuel Dumas

    Untargeted metabolomics based on Ultra High-Performance Liquid Chromatography coupled to High-Resolution Mass Spectrometry (UHPLC-HRMS) is a powerful tool widely used in various research domains, including large-scale clinical studies. However, current approaches for comparing untargeted metabolomic methods typically rely on a limited set of representative analytes due to their high cost and limited availability, potentially introducing bias given the vast chemical diversity of the detectable metabolome. This study proposes a data-driven strategy to systematically compare and rank untargeted UHPLC-HRMS methodologies by leveraging metabolite annotations from the public reference spectral libraries deposited in the Global Natural Products Social molecular network (GNPS) as a proxy for chemical coverage. We assessed 23 methodologies: 15 reverse-phase and 8 HILIC-phase from six metabolomic platforms using commercial human serum samples. Across all methods, a combined total of 2448 unique metabolites were annotated at MSI level 2, covering 57 chemical classes and 13 superclasses, as defined by the ClassyFire ontology. Methods were ranked using a weighted composite system incorporating reproducibility (RSD 0.9), and chemical diversity coverage quantified by the Shannon diversity index. The reliability of GNPS-based annotations was validated against 129 metabolites for which authentic standards were available in our in-house library, all of which were correctly confirmed, supporting the reliability of the MSI level 2 annotations. Applied to clinical serum samples from the PrevenDIAB study, the best-performing method combination (P1−H and P6−C18) detected 883 metabolites meeting both quality criteria, of which 98% were shared with the commercial serum results. Our findings demonstrate that this framework provides a practical, scalable, and cost-effective complementary approach to standard-based validation for the comparative evaluation of untargeted metabolomics methods.

  • Open Access

    Schoenoplectus californicus (C.A. Mey.) Soják: Chemical Profile, Antioxidant Capacity, Psychopharmacological Exploration and Analgesic Activity

    by Julio Campos-Florián, Gladys Galliani-Huamanchumo, Alessandra Victoria Campos-Bazán, Betsabé Chunga-Flores, Inés Castro-Dionicio, Víctor E. Villarreal-La Torre, Lucia Fátima Flores-Atoche, Lucia Gonzales-Mendez, Gianfranco Ramos-Farfán, José Condor-Goytizolo, et al.

    Schoenoplectus californicus, a macrophyte from Peruvian marine–coastal wetlands, is traditionally used for medicinal purposes, yet its pharmacological potential remains insufficiently explored. This study evaluated the chemical profile, antioxidant capacity, psychopharmacological effects, and analgesic activity of a hydroethanolic extract from its rhizomes. Phytochemical screening and LC–MS/MS analyses were performed to characterize secondary metabolites. Antioxidant activity was assessed using DPPH and ABTS assays, while in vivo anxiolytic, sedative, and analgesic effects were evaluated in Balb/c mice through open field, elevated plus maze, rotarod, analgesimeter, tail-flick, and hot plate tests, with diazepam and tramadol as reference drugs. In silico PASS and BOILED-Egg analyses were used to predict pharmacological mechanisms and central nervous system permeability. The extract contained flavonoids, phenolic compounds, and stilbenes and exhibited notable antioxidant activity (IC50: 0.7319 mg/mL for DPPH and 0.6207 mg/mL for ABTS). Anxiolytic effects were observed at 50 mg/kg, sedative effects at 200 mg/kg, and significant analgesic activity at 50 mg/kg. Several compounds were predicted to cross the blood–brain barrier, with inhibition of GABA aminotransferase suggested as a potential mechanism. Acute toxicity was detected (LD50 > 2000 mg/kg). These findings support S. californicus as a promising source of neuroactive and analgesic compounds, although further mechanistic and dose-optimization studies are required.


  • Caractérisation des métabolites secondaires responsables de l'activité anti-Helicobacter pylori d'une plante médicinale péruvienne Cordia lutea Lam. (Boraginaceae)

    by Inés Castro Dionicio

    Cordia lutea Lam. (Flor de Overo) est une plante utilisée en médecine traditionnelle péruvienne pour le traitement des troubles gastro-intestinaux, des hépatites et des douleurs rénales. Onze composés ont été isolés à partir de l'extrait éthanolique des fleurs de cette plante médicinale sur la base d'un fractionnement bioguidé. Dix de ces composés (cordiasecosides A-J), représentent les premiers exemples de 9,10-seco-29-norcycloartane glycosides. Leurs structures ont été déterminées par des analyses de données RMN et MS ainsi que des analyses cristallographiques aux rayons X. Ces composés ont montré une activité in vitro anti-Helicobacter pylori significative et aucune activité contre Escherichia coli ou Pseudomonas aeruginosa. Une activité significative a été observée pour les cordiasecosides E et F contre Staphylococcus aureus. Tous les composés présentent une faible cytotoxicité contre les cellules RAW 264,7. Les activités antileishmaniales et antiplasmodiales in vitro des cordiasecosides A à F ont également été évaluées. Le présent travail de recherche comprend aussi l'isolement de deux composés précédemment décrits dans la littérature : l'acide isorinique et la quercétine 3-robinobioside. Enfin, l'étude botanique et chimique de différents lots de matériel végétal achetés sur différents marchés a également été réalisée, dans le but d'évaluer la variabilité de la drogue et de proposer des pistes pour contrôler sa qualité.

  • Open Access

    A gut microbiome-kidney-heart axis predictive of future cardiovascular diseases

    by Kanta Chechi, Rima Chakaroun, Antonis Myridakis, Sofia K Forslund-Startceva, Sebastien Fromentin, Trine Nielsen, Judith Aron-Wisneswky, Eugeni Belda, Edi Prifti, Pierre Bel Lassen, et al.

    Cardiovascular diseases (CVD) remain a major global health challenge. Early markers of disease initiation and progression are urgently needed. We, and others, have previously shown changes in the gut microbiome in association with metabolic and CVD. Here, we demonstrate that gut microbiome-related changes can be detected in association with subclinical variations in heart and kidney function. Markers related to gut microbial metabolism of aromatic amino acids, phenylalanine and tyrosine, associate with circulating pro-atrial natriuretic peptide and estimated glomerular filtration rate in a metabolically healthy European population. Observational and genetic evidence further identify microbiome-related metabolites as mediators of this gut microbiome-kidney axis, with their baseline levels associating with incident CVD in an external Canadian population. Altogether, our work suggests that the gut microbiome interacts with the cardiorenal axis and participates in an interorgan crosstalk affecting host physiology and risk of CVD.


  • Open Access

    Prominent mediatory role of gut microbiome in the effect of lifestyle on host metabolic phenotypes

    by Solia Adriouch, Eugeni Belda, Timothy D. Swartz, Sofia Forslund, Edi Prifti, Judith Aron-Wisnewsky, Rima Chakaroun, Trine Nielsen, Christine Poitou, Pierre Bel-Lassen, et al.

    Lifestyle factors influence both gut microbiome composition and host metabolism, yet their combined and mediating effects on host phenotypes remain poorly characterized in cardiometabolic populations. In 1,643 participants from the MetaCardis study, we developed a composite lifestyle score (QASD: dietary quality, physical activity, smoking, and diet diversity) that outperformed individual lifestyle variables in explaining microbial gene richness and exhibited a significant impact on the gut microbiome composition. While bidirectional pathways linking the QASD score, host phenotypes, and microbiome composition were assessed, causal inference-based mediation analyses indicated stronger effects when the microbiome was modeled as the mediator variable, particularly in relation to the insulin resistance-associated profile. Microbiome gene richness emerged as a key mediator explaining 27.8% of QASD score's effect on the insulin resistance marker (HOMA-IR), while no significant mediation was observed on BMI. Extended mediation analyses on microbial species and serum metabolomics deconfounded for drug use and clinical profiles identified 47 mediations where microbial taxa mediated more than 20% of the effect of the QASD score on serum metabolites associated with insulin resistance. Notably, several Faecalibacterium lineages enriched in individuals with high QASD score played a significant mediatory role in increasing the serum biomarkers of microbiome diversity (as cinnamoylglycine or 3-phenylpropionate). Conversely, elevated levels of secondary bile acids in individuals with low QASD scores were strongly mediated by high levels of Clostridium bolteae. These findings highlight distinct and clinically relevant microbiome pathways linking lifestyle behaviors to cardiometabolic risks.One sentence summary:The gut microbiome mediates the impact of diet quality and diversity, physical activity and smoking status - combined in a composite lifestyle score - on cardiometabolic phenotypes.


  • A New Rare Halogenated Depside from Lichen and Study of its Anti‐Proliferative Activity

    by Ajoy K. Bauri, Ines Castro Dionicio, Eric Salinas Arellano, Jonathan G. Jeyaraj, Sabine Foro, Esperanza J. Carcache de Blanco

    Lichens are a symbiotic association of algae and fungus, belonging to the family Parmeliaceae. Some lichen species are edible and used as an active ingredient for preparation of exotic spices as well as folklore medicine to cure different kinds of ailments. A specimen of lichen was collected from Munner in the Kerala State of South India for chemical profiling. Chemical analyses of the diethyl ether extract of the defatted lichen led to the isolation of six phenols 1–6 with variation of relative abundance. Amongst them, the relative abundance of compound 3 was the greatest (1 % of crude extract) and it was identified as atranorin. The structures of known compounds were confirmed by comparison of their 1H‐NMR, 13C NMR, and mass data with published values available in the literature. In vitro bioassay for anti‐proliferative activity of these compounds has been conducted against various human cancer cell lines in comparison with paclitaxel as control using SRB assay. Interestingly, a new compound 5 was found along with previously reported compounds from this lichen. This new compound was designated as fluoroatranorin 5 which was reported for the first time herein. The structural characterization of a new depside was determined by spectral methods such as 1H‐NMR, 13C NMR, 19F NMR, IR, LC‐HRESI‐MS, and LC–MS/MS study. Its structure was confirmed by single crystal X‐ray diffraction study. This new compound was designated as fluoroatranorin 5 which was reported first time herein. Anti‐proliferative activity of all these compounds was evaluated against six different cancer cell lines. The inhibitory activity, IC50 value of compounds 1–3 and 5 exhibited at 99.64, 102.04, 109.20, 53.0 and 2.4 μM on cancer cell lines HT‐29 (colon), Hela (cervical), HT‐29, HPAC (pancreas) and A2780 (ovarian cancer cell line) respectively in comparison with paclitaxel as control. The new compound 5 exhibited significant activity with IC50 value 2.4 μM on A2780 ovarian cancer cell line.


  • Open Access

    Evaluación de la toxicidad de chalconas sintéticas con potencial anti-Leishmania en ratones BALB/c

    by Karina Cancino, Inés Castro, Carlos Yauri, Valérie Jullian, Jorge Arévalo, Michel Sauvain, Vanessa Adaui, Denis Castillo

    Objetivo: Evaluar la toxicidad de tres chalconas sintéticas administradas por vía intraperitoneal en ratones BALB/c. Materiales y métodos: La dosis letal media (DL50) se estimó por el método Up-and-Down de Dixon. La toxicidad subcrónica de las chalconas se evaluó a 20 y 40 mg/kg por 21 días. Se evaluó el efecto tóxico a nivel de comportamiento, fisiológico, bioquímico e histológico. Resultados: La chalcona 43 generó moco en las heces, daño visceral (hígado) y alteración en el coeficiente de órganos (riñón, p = 0,037 y cerebro, p = 0,008) en comparación con el grupo control. Además, en el análisis histológico se observó que esta chalcona produjo edema, inflamación y necrosis en los órganos evaluados, aunque no hubo diferencia significativa con el control. Todos los parámetros bioquímicos no difirieron significativamente entre los grupos de tratamiento a dosis de 40 mg/kg y el control. Conclusiones: La DL50 para las tres chalconas fue superior a 550 mg/kg de peso corporal. Las chalconas 40 y 42 son relativamente no tóxicas. Ambas pueden considerarse seguras para la aplicación vía intraperitoneal en ratones BALB/c y, en consecuencia, son posibles candidatas para ser usadas en el tratamiento contra las leishmaniosis.


  • Integrating Traditional and Modern Medicine: Perspectives from Ethnobotany, Medical Anthropology, Microbiology, and Pharmacy

    by Gail R. Willsky, Rainer W. Bussmann, Mayar L. Ganoza-Yupanqui, Gonzalo Malca-Garcia, Inés Castro, Douglas Sharon


  • Structural Characterization and Anti-infective Activity of 9,10-Seco-29-norcycloartane Glycosides Isolated from the Flowers of the Peruvian Medicinal Plant Cordia lutea

    by Inés Castro, Nicolas Fabre, Sandra Bourgeade-Delmas, Nathalie Saffon, Chloé Gandini, Michel Sauvain, Denis Castillo, Geneviève Bourdy, Valérie Jullian

    Six new secocycloartane glycosides (1–6) were isolated from the ethanol extract of the flowers of Cordia lutea Lam. on the basis of bioassay-guided fractionation. Their structures were determined by the application of NMR and MS data analyses together with X-ray crystallographic analyses for compounds 1 and 2. Compounds 1–6 represent the first examples of 9,10-seco-29-norcycloartane glycosides. These compounds showed significant in vitro anti-Helicobacter pylori activity, and no activity against either Escherichia coli or Pseudomonas aeruginosa. Significant activity was observed for 5 and 6 against Staphylococcus aureus. All compounds displayed weak cytotoxicity against RAW 264.7 cells. The in vitro antileishmanial and antiplasmodial activities of 1–6 were also evaluated.


  • Open Access

    Serum sCD26 for colorectal cancer screening in family-risk individuals: comparison with faecal immunochemical test

    by O Otero-Estévez, L De Chiara, F J Rodríguez-Berrocal, M Páez de la Cadena, J Cubiella, I Castro, C Gonzalez-Mao, V Hernandez, V S Martínez-Zorzano

    Background: The development of specific screening programs for individuals with a family history of colorectal cancer (CRC) is a priority. This study evaluates the diagnostic performance of serum soluble CD26 (sCD26) in family-risk individuals and compares this marker with the faecal immunochemical test for the detection of advanced neoplasia (AN) (CRC or advanced adenomas; AA). Methods: Five hundred and sixteen asymptomatic individuals with at least one first-degree relative with CRC were included. Serum sCD26 was measured in all the individuals who also underwent a colonoscopy (53 AA and four cancer cases were found) and a faecal immunochemical test. Results: Setting specificity to 90% and 95%, respectively, sCD26 showed a sensitivity of 39.6% and 28.3% for AA, and of 42.1% and 28.1% for AN. The combination of sCD26 and the faecal test detected AA and AN with a 52.8% and 56.1% sensitivity, corresponding to 93.5% specificity. Conclusions: The combination of serum sCD26 and the faecal blood test could result a valuable strategy for detecting AN in familial-risk CRC screening.